Status Epilepticus: Stopping runaway seizures with a chill pill

The neuropeptide neurotensin can reduce status epilepticus and its associated consequences through induction of therapeutic hypothermia when bound to a molecule that can penetrate the blood-brain barrier.
  1. Gordon F Buchanan  Is a corresponding author
  1. University of Iowa, Carver College of Medicine, United States

The brain consists of electrically excitable cells called neurons, which work in concert to regulate brain function. Sometimes, these cells become aberrantly connected and may activate together as a small network, leading to abnormal bursts of electrical activity known as seizures. Seizures disrupt the flow of messages between neurons and can lead to involuntary changes in behavior, sensation, and body movement or function.

Recurrent seizures are the hallmark of disease in patients with epilepsy (Langbein et al., 2024). Seizures that last a long time, also known as status epilepticus, can be life-threatening and require immediate treatment. Unfortunately, status epilepticus is often very difficult to control, leading to a high rate of morbidity and mortality (Kämppi et al., 2024).

Efforts to develop better therapies for status epilepticus are ongoing (O’Kula and Hill, 2024; Kishihara et al., 2024). One way to manage these kinds of seizures involves inducing hypothermia in the body and the brain to reduce cellular excitability (Kirmani et al., 2021). However, lowering body temperature using physical means, such as cooling blankets or infusions of cooled saline, can negatively affect the body. A more targeted way would be through medication that could pharmacologically alter body temperature.

While drugs targeting the biochemical pathways that regulate temperature homeostasis can lower body temperature, they often fail to reach the brain due to the blood-brain barrier, a protective semipermeable membrane between the blood and the brain. Thus, many drugs that lower body temperature do not markedly reduce brain temperature and have little to no effect on status epilepticus. Now, in eLife, Lotfi Ferhat, Michel Khrestchatisky and colleagues report a new approach to specifically reduce brain temperature and stop status epilepticus (Ferhat et al., 2024).

The researchers, who are based at various research institutes in France, targeted the biochemical pathway involving the signaling molecule neurotensin, which is known to regulate body temperature by lowering the set point on the thermostat that governs body temperature. As neurotensin cannot cross the blood-brain barrier, Ferhat et al. combined neurotensin with a molecule known to penetrate the brain and tested its effectiveness in mice. Specifically, these ‘conjugated’ versions were able to bind the low-density lipoprotein receptor (LDLR), which then transported the molecule across the blood-brain barrier intothe brain.

The researchers developed several conjugate proteins, and through a series of careful testing, identified one to employ throughout the study. The conjugate formed by this protein and neurotensin was successful in reaching the brain, inducing hypothermia, and reducing the seizures and cognitive and inflammatory changes associated with status epilepticus. However, it still needs to be confirmed that neurotensin-induced hypothermia alone is responsible for alleviating the effects associated with status epilepticus.

Regardless, the possibility of pharmacologically induced hypothermia for managing status epilepticus is exciting. Refractory status epilepticus (which continues despite treatment) is a dreadful condition with extremely high rates of mortality, despite the barrage of currently available therapies. Improved treatment modalities are sorely needed. While the findings of Ferhat et al. are promising, more needs to be learned about the safety of these treatments for the rest of the body. Such studies could be first trialled in animals but would later need to be replicated in humans. Moreover, while it is assumed that pharmacological means to induce hypothermia would have fewer negative consequences than physical means, this needs to be empirically evaluated. Hypothermia itself can have profound negative consequences, so the degree of hypothermia would need to be tightly monitored (Lu et al., 2024).

The extent of neuroprotection afforded by pharmacologically induced hypothermia could likely extend to other forms of neural injury, including stroke, post-anoxic brain injury or traumatic brain injury (Lin et al., 2024). Thus, implications for this promising work are potentially extremely far-reaching.

References

Article and author information

Author details

  1. Gordon F Buchanan

    Gordon F Buchanan is in the University of Iowa, Carver College of Medicine, Iowa City, United States

    For correspondence
    gordon-buchanan@uiowa.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2371-4455

Publication history

  1. Version of Record published:

Copyright

© 2024, Buchanan

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 311
    views
  • 24
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gordon F Buchanan
(2024)
Status Epilepticus: Stopping runaway seizures with a chill pill
eLife 13:e102055.
https://doi.org/10.7554/eLife.102055

Further reading

    1. Cell Biology
    2. Neuroscience
    Jun Sun, Francisca Rojo-Cortes ... Alicia Hidalgo
    Research Article

    Experience shapes the brain as neural circuits can be modified by neural stimulation or the lack of it. The molecular mechanisms underlying structural circuit plasticity and how plasticity modifies behaviour are poorly understood. Subjective experience requires dopamine, a neuromodulator that assigns a value to stimuli, and it also controls behaviour, including locomotion, learning, and memory. In Drosophila, Toll receptors are ideally placed to translate experience into structural brain change. Toll-6 is expressed in dopaminergic neurons (DANs), raising the intriguing possibility that Toll-6 could regulate structural plasticity in dopaminergic circuits. Drosophila neurotrophin-2 (DNT-2) is the ligand for Toll-6 and Kek-6, but whether it is required for circuit structural plasticity was unknown. Here, we show that DNT-2-expressing neurons connect with DANs, and they modulate each other. Loss of function for DNT-2 or its receptors Toll-6 and kinase-less Trk-like kek-6 caused DAN and synapse loss, impaired dendrite growth and connectivity, decreased synaptic sites, and caused locomotion deficits. In contrast, over-expressed DNT-2 increased DAN cell number, dendrite complexity, and promoted synaptogenesis. Neuronal activity modified DNT-2, increased synaptogenesis in DNT-2-positive neurons and DANs, and over-expression of DNT-2 did too. Altering the levels of DNT-2 or Toll-6 also modified dopamine-dependent behaviours, including locomotion and long-term memory. To conclude, a feedback loop involving dopamine and DNT-2 highlighted the circuits engaged, and DNT-2 with Toll-6 and Kek-6 induced structural plasticity in this circuit modifying brain function and behaviour.

    1. Neuroscience
    Walter Senn, Dominik Dold ... Mihai A Petrovici
    Research Article

    One of the most fundamental laws of physics is the principle of least action. Motivated by its predictive power, we introduce a neuronal least-action principle for cortical processing of sensory streams to produce appropriate behavioral outputs in real time. The principle postulates that the voltage dynamics of cortical pyramidal neurons prospectively minimizes the local somato-dendritic mismatch error within individual neurons. For output neurons, the principle implies minimizing an instantaneous behavioral error. For deep network neurons, it implies the prospective firing to overcome integration delays and correct for possible output errors right in time. The neuron-specific errors are extracted in the apical dendrites of pyramidal neurons through a cortical microcircuit that tries to explain away the feedback from the periphery, and correct the trajectory on the fly. Any motor output is in a moving equilibrium with the sensory input and the motor feedback during the ongoing sensory-motor transform. Online synaptic plasticity reduces the somatodendritic mismatch error within each cortical neuron and performs gradient descent on the output cost at any moment in time. The neuronal least-action principle offers an axiomatic framework to derive local neuronal and synaptic laws for global real-time computation and learning in the brain.